An Open Label Extension Study to Evaluate Inhaled Treprostinil in Adult PH With ILD Including CPFE

Stopped Inhaled treprostinil became commercially available in the US following its approval for PH-ILD

Conditions

• Pulmonary Hypertension
• Interstitial Lung Disease
• Combined Pulmonary Fibrosis and Emphysema

Interventions

• DRUG: Inhaled Treprostinil

Sponsor

United Therapeutics